Prostate cancer remains a significant public health problem. The current approach with prostate-specific antigen (PSA)-based screening has questionable effects on prostate cancer–specific mortality ...
Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man's risk of being diagnosed with prostate cancer from around 5--9 percent to around 4-6 percent during up to ...
This article presents background information and highlights key findings from a managed care perspective related to enlarged prostate (EP) in Medicare-eligible patients. This article does not provide ...
Objective: The purpose of this study was to examine the rates of acute urinary retention (AUR) and surgery after initiating 5-alpha reductase inhibitor (5ARI) therapy and to compare the 2 currently ...
Data on whether 5-ARIs increase the risk of prostate cancer-specific mortality have been mixed. Use of 5-alpha-reductase inhibitors (5-ARIs) does not increase the risk of dying from prostate cancer, ...
To earn CME related to this news article, click here. February 25, 2009 — A new joint guideline produced by the American Society of Clinical Oncology (ASCO) and the American Urological Association ...
A new study published in The Journal of Sexual Medicine reveals that, for the first time, 5a-reductase inhibitors commonly used to treat urinary problems in patients with benign prostatic hyperplasia ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. While 5-alpha-reductase inhibitor use did not increase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results